Rockefeller Capital Management
CMPX icon

Rockefeller Capital Management’s Compass Therapeutics CMPX Stock Holding History

Rockefeller Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Sell
4,814
-5,368
-53% -$15.8K ﹤0.01% 3997
2026
Q1 		$53.9K Buy
10,182
+8,140
+399% +$47K ﹤0.01% 3238
2025
Q4 		$11K Buy
+2,042
New +$9.43K ﹤0.01% 3768

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rockefeller Capital Management's CMPX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Compass Therapeutics (CMPX) stake by 53% in Q2 2026, selling an estimated $15.8K and leaving 4,814 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3997.

Rockefeller Capital Management first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $53.9K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Rockefeller Capital Management held 4,814 shares of Compass Therapeutics worth $10.5K as of Q2 2026.
  • Rockefeller Capital Management sold 5,368 Compass Therapeutics shares in Q2 2026, an estimated $15.8K.
  • Compass Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3997 holding.
  • Rockefeller Capital Management first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Compass Therapeutics position peaked at $53.9K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.